14 assets in Acute Myeloid Leukemia With Mutated NPM1

Therapeutic assets addressing Acute Myeloid Leukemia With Mutated NPM1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Acute Myeloid Leukemia With Mutated NPM1	Shen yang	P3	B (63)
Azacitidine Acute Myeloid Leukemia With Mutated NPM1	Shen yang	P2	B (60)
Daunomycin Acute Myeloid Leukemia With Mutated NPM1	Shen yang	P2	B (58)
Venetoclax Acute Myeloid Leukemia With Mutated NPM1	Kura Oncology, Inc.	P2	B (58)
BN104 Acute Myeloid Leukemia With Mutated NPM1	Institut de Recherches Internationales Servier (I.R.I.S.)	P1/2	CC (47)
Mezigdomide Acute Myeloid Leukemia With Mutated NPM1	Massachusetts General Hospital	P1	CC (43)
Revumenib Acute Myeloid Leukemia With Mutated NPM1	National Cancer Institute (NCI)	P1	CC (43)
Bsb-2002 Acute Myeloid Leukemia With Mutated NPM1	BlueSphere Bio, Inc	P1	CC (41)
Fludarabine Acute Myeloid Leukemia With Mutated NPM1	Kura Oncology, Inc.	P1	CC (41)
Gilteritinib Acute Myeloid Leukemia With Mutated NPM1	Kura Oncology, Inc.	P1	CC (41)
Idarubicin Acute Myeloid Leukemia With Mutated NPM1	Kura Oncology, Inc.	P1	CC (41)
Quizartinib Acute Myeloid Leukemia With Mutated NPM1	Kura Oncology, Inc.	P1	CC (41)
Ziftomenib Acute Myeloid Leukemia With Mutated NPM1	Massachusetts General Hospital	P1	CC (41)
Entospletinib Acute Myeloid Leukemia With Mutated NPM1	Kronos Bio	P3	CC (40)